BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Xuanzhu Biopharmaceutical’s Bireociclib (Xuanyuening®) Approved in China, Setting New Benchmark in HR+/HER2- Breast Cancer Treatment

National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade...

May 19, 2025 | News

InnoCare Pharma Doses First Patient in Phase II/III Trial of Soficitinib for Vitiligo in China

InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has...

May 19, 2025 | News

Shanghai Ark Biopharmaceutical Announces Positive Phase II Results for AK3280 in Idiopathic Pulmonary Fibrosis

Shanghai Ark Biopharmaceutical Co., Ltd. announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of id...

May 16, 2025 | News

WuXi Biologics to Divest Leverkusen Plant to Terumo for €150M, Refocuses on Global DP Expansion

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has entered into ...

May 15, 2025 | News

Sanyou Biopharmaceuticals and TransRecoBio Form Strategic Alliance to Accelerate Innovative Formulation Development

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Biopharmaceuticals") and TransRecoBio (Wenzhou) Biotechnology Co., Ltd. ("TransRecoBio") officially...

May 14, 2025 | News

InnoCare’s Mesutoclax Becomes First BCL2 Inhibitor to Receive Breakthrough Therapy Designation in China

-InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced&nbs...

May 13, 2025 | News

Minghui Pharma Licenses B7-H3 ADC MHB088C to Qilu for Greater China in RMB 1.345 Billion Deal

Minghui Pharmaceutical , a late-stage clinical biopharmaceutical company, announced an exclusive licensing and collaboration agreement with Qilu Phar...

May 12, 2025 | News

CARsgen Reports Promising Early Data for Allogeneic BCMA CAR-T CT0596 in Relapsed/Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Limited a company focused on developing innovative CAR T-cell therapies, announces preliminary clinical data for CT0596...

May 12, 2025 | News

BioDlink Supports Junshi Biosciences in Achieving IND Approval for JS212, Its First Bispecific ADC

BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212, the company...

May 09, 2025 | News

China Grants Full Approval to Everest Medicines’ NEFECON® as First and Only Etiological Treatment for IgA Nephropathy

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

May 07, 2025 | Regulatory

Beijing Tide Begins Phase II Trial of First-in-Class Non-Opioid CPSP Drug TRD205

Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class ...

May 06, 2025 | News

Fangzhou Launches Otsuka’s Iclusig® Online for Leukemia Care in China

Fangzhou Inc. , a leader in Internet healthcare solutions, announced the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhi...

May 06, 2025 | News

Nutshell Therapeutics Receives FDA IND Clearance for First-in-Human Trial of NTS071 Targeting p53 Y220C Mutation

Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical ...

May 05, 2025 | News

InnoCare’s Zurletrectinib Granted Priority Review in China for NTRK Fusion-Positive Solid Tumors

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that its new genera...

May 05, 2025 | News

Stay Connected